دورية أكاديمية
Hydroxychloroquine and COVID-19: can we learn from the use of rituximab in systemic lupus erythematosus?
| العنوان: | Hydroxychloroquine and COVID-19: can we learn from the use of rituximab in systemic lupus erythematosus? |
|---|---|
| المؤلفون: | Lekpa FK; Internal Medicine Department, Douala General Hospital, Douala, Cameroon.; Department of Internal Medicine and Specialties, Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon.; The University of Dschang Taskforce for the Elimination of COVID-19 (UNITED#COVID-19), Dschang, Cameroon., Ngahane BHM; Internal Medicine Department, Douala General Hospital, Douala, Cameroon., Njonnou SRS; Department of Internal Medicine and Specialties, Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon.; The University of Dschang Taskforce for the Elimination of COVID-19 (UNITED#COVID-19), Dschang, Cameroon., Fouda H; Internal Medicine Department, Douala General Hospital, Douala, Cameroon., Halle MP; Internal Medicine Department, Douala General Hospital, Douala, Cameroon., Njankouo YM; Internal Medicine Department, Douala General Hospital, Douala, Cameroon., Dzudie A; Internal Medicine Department, Douala General Hospital, Douala, Cameroon.; The University of Dschang Taskforce for the Elimination of COVID-19 (UNITED#COVID-19), Dschang, Cameroon., Choukem SP; Internal Medicine Department, Douala General Hospital, Douala, Cameroon.; Department of Internal Medicine and Specialties, Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon.; The University of Dschang Taskforce for the Elimination of COVID-19 (UNITED#COVID-19), Dschang, Cameroon.; Health and Human Development (2HD) Research Network, Douala, Cameroon., Luma HN; Internal Medicine Department, Douala General Hospital, Douala, Cameroon. |
| المصدر: | The Pan African medical journal [Pan Afr Med J] 2021 Apr 15; Vol. 38, pp. 372. Date of Electronic Publication: 2021 Apr 15 (Print Publication: 2021). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: African Field Epidemiology Network Country of Publication: Uganda NLM ID: 101517926 Publication Model: eCollection Cited Medium: Internet ISSN: 1937-8688 (Electronic) NLM ISO Abbreviation: Pan Afr Med J Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Kampala, Uganda : African Field Epidemiology Network |
| مواضيع طبية MeSH: | COVID-19 Drug Treatment*, Hydroxychloroquine/*therapeutic use , Immunologic Factors/*therapeutic use , Lupus Erythematosus, Systemic/*drug therapy , Rituximab/*therapeutic use, Humans |
| مستخلص: | Rituximab (RTX), a chimeric monoclonal anti-CD20 antibody has become part of the standard therapy for patients with CD20-expressing B-cell lymphoma and rheumatoid arthritis. After encouraging results with open studies in systemic lupus erythematosus (SLE), RTX has not shown its effectiveness in randomized controlled trials. However, its efficacy has been validated in renal, hematological, and neuropsychiatric disorders. Understanding the history of RTX in SLE would be instructive in the hydroxychloroquine (HCQ) saga in COVID-19. Three steps would be necessary and sufficient before definitively closing the debate: 1) determine the effective and safe dose of HCQ, as well as the minimum duration of treatment in COVID-19; 2) define the profile of patients in whom HCQ would be more likely to be effective (especially in asymptomatic patients and/or at the onset of the first signs of the disease) and 3) conduct one or more multicentre RCT to evaluate the efficacy and safety of HCQ in COVID-19 in SSA. Competing Interests: The authors declare no competing interests. (Copyright: Fernando Kemta Lekpa et al.) |
| References: | Ann Rheum Dis. 2019 Jun;78(6):736-745. (PMID: 30926722) Lupus. 2013 Dec;22(14):1489-503. (PMID: 24135078) Arthritis Rheum. 2010 Aug;62(8):2458-66. (PMID: 20506527) Med Anthropol Q. 2020 Dec;34(4):525-541. (PMID: 33210338) Nat Prod Commun. 2020 Aug 14;15(8):1934578X20945086. (PMID: 34191921) Res Rep Trop Med. 2020 Sep 17;11:61-72. (PMID: 32982538) Pan Afr Med J. 2020 May 26;35(Suppl 2):48. (PMID: 33623573) Int J Antimicrob Agents. 2020 Jul;56(1):105949. (PMID: 32205204) Pan Afr Med J. 2020 Sep 15;37(Suppl 1):9. (PMID: 33294110) Cochrane Database Syst Rev. 2021 Feb 12;2:CD013587. (PMID: 33624299) |
| فهرسة مساهمة: | Keywords: COVID-19; Hydroxychloroquine; randomized controlled trials; rituximab |
| المشرفين على المادة: | 0 (Immunologic Factors) 4F4X42SYQ6 (Rituximab) 4QWG6N8QKH (Hydroxychloroquine) |
| تواريخ الأحداث: | Date Created: 20210809 Date Completed: 20210913 Latest Revision: 20221207 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC8308936 |
| DOI: | 10.11604/pamj.2021.38.372.29087 |
| PMID: | 34367451 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1937-8688 |
|---|---|
| DOI: | 10.11604/pamj.2021.38.372.29087 |